BCR and ovarian neoplasm: Notably, the genes of this signature have been previously recognized in a number of independent studies, overlapping substantially with prognostic and therapy-predictive B-cell signatures in breast cancer [9, 54–56], an IgG metagene in breast cancer [57] and a gene signature of B-cell TILs in breast and ovarian tumor subtypes associated with prognostic low-diversity B-cell receptor (BCR) gene segments [58].